semaglutide oral cardiovascular indication news 2025 soul Congreso ACC. 25: Semaglutide Reduces Events in People With Type 2 Diabetes With Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial EASD 2025: Pooled analysis highlights

In patients who did not receive SGLT-2 inhibitors at baseline or during the study, 20.7% experienced the primary outcome with semaglutide and 27.2% experienced the primary outcome with placebo (HR 0.70, 95% CI 0.590.82) [24]

10.1007/s00125-016-3874-y Diabetologia 19 GautronL.ElmquistJ

Our latest report The rise of the anxious worker New findings reveal that anxiety in the workforce is directly impacting American employers, driving up overall health care spend, and impeding workforce productivity

"2026 FEHB/PSHB Formulary." Zepbound (tirzepatide) listed at Tier 3/4 (specialty tier) for weight management indication with prior authorization

Similarly, exenatide-4 inhibits hepatocarcinogenesis independent of obesity and MASH resolution, acting through the cAMP-PKA-EGFR-STAT3 axis and mTOR modulation to suppress proliferation and reduce HCC multiplicity (Zhou et al., 2017)

Unlabeled Use Disclosure: Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA